Zeibdawi A R, Pryzdial E L
Research and Development Department, the Canadian Blood Services, Department of Biochemistry, University of Ottawa, Ottawa, Ontario K1G 4J5, Canada.
J Biol Chem. 2001 Jun 8;276(23):19929-36. doi: 10.1074/jbc.M004711200. Epub 2001 Mar 16.
The coagulation cofactor Va (FVa) is a noncovalent heterodimer consisting of a heavy chain (FVaH) and a light chain (FVaL). Previously, the fibrinolytic effector plasmin (Pn) has been shown to inhibit FVa function. To understand this mechanism, the fragmentation profile of human FVa by Pn and the noncovalent association of the derived fragments were determined in the presence of Ca(2+) using anionic phospholipid (aPL)-coated microtiter wells and large (1 microm) aPL micelles as affinity matrices. Following Pn inactivation of aPL-bound FVa, a total of 16 fragments were observed and their NH(2) termini sequenced. These had apparent molecular weights and starting residues as follows (single letter abbreviation is used): 50(L1766), 48(L1766), 43(Q1828), 40(Q1828), 30(S1546), 12(T1657), and 7(S1546) kDa from FVaL; and 65(A1), 50(A1), 45(A1), 34(S349), 30(L94), 30(M110), and 3 small <5(W457, W457, and K365) kDa from FVaH. Of these, 50(L1766), 48(1766), 43(Q1828), and 40(Q1828) spanning the C1/C2 domains, and 30(L94), but not the similar 30(M110), positioned within the A1 domain remained associated with aPL. These were detected antigenically during Pn- or tissue plasminogen activator-mediated lysis of fibrin clot formed in plasma. Chelation by EDTA dissociated the 30(L94)-kDa fragment, which was observed to associate with intact FVaL upon recalcification, indicating that the Leu-94 to Lys-109 region of the A1 domain plays a critical role in the FVaL and FVaH Ca(2+)-dependent association. By using domain-specific monoclonal antibodies and an assay for thrombin generation, loss of FVa prothrombinase function was coincident with proteolysis at sites in the A2 and A3 domains resulting in their dissociation. Inactivation of FV or FVa by Pn was independent of the thrombophilic R506Q mutation. These results identify the molecular composition of Pn-cleaved FVa that remains bound to membrane as largely A1-C1/C2 in the presence of Ca(2+) and suggest that Pn inhibits FVa by a process involving A2 and A3 domain dissociation.
凝血辅因子Va(FVa)是一种由重链(FVaH)和轻链(FVaL)组成的非共价异二聚体。此前,已证明纤溶效应物纤溶酶(Pn)可抑制FVa功能。为了解该机制,在存在Ca(2+)的情况下,使用阴离子磷脂(aPL)包被的微量滴定孔和大的(1微米)aPL微团作为亲和基质,测定了Pn对人FVa的片段化谱以及衍生片段的非共价缔合。在aPL结合的FVa被Pn失活后,共观察到16个片段并对其NH(2)末端进行了测序。这些片段的表观分子量和起始残基如下(使用单字母缩写):来自FVaL的50(L1766)、48(L1766)、43(Q1828)、40(Q1828)、30(S1546)、12(T1657)和7(S1546)kDa;以及来自FVaH的65(A1)、50(A1)、45(A1)、34(S349)、30(L94)、30(M110)和3个小于5(W457、W457和K365)kDa的小片段。其中,跨越C1/C2结构域的50(L1766)、48(1766)、43(Q1828)和40(Q1828),以及位于A1结构域内的30(L94),而非类似的30(M110),仍与aPL缔合。在血浆中形成的纤维蛋白凝块被Pn或组织纤溶酶原激活剂介导溶解期间,通过抗原检测到这些片段。EDTA螯合使30(L94)kDa片段解离,重新钙化后观察到该片段与完整的FVaL缔合,表明A1结构域的Leu - 94至Lys - 109区域在FVaL和FVaH的Ca(2+)依赖性缔合中起关键作用。通过使用结构域特异性单克隆抗体和凝血酶生成测定法,FVa凝血酶原酶功能的丧失与A2和A3结构域位点的蛋白水解导致它们解离同时发生。Pn对FV或FVa的失活与血栓形成倾向的R506Q突变无关。这些结果确定了在存在Ca(2+)的情况下,仍与膜结合的Pn切割的FVa的分子组成主要为A1 - C1/C2,并表明Pn通过涉及A2和A3结构域解离的过程抑制FVa。